Crisaborole和Apremilast:具有相似作用机制，不同适应症的PDE4抑制剂用于炎症性皮肤病的治疗

Pharmacology & Pharmacy Pub Date : 2018-09-07 DOI:10.4236/PP.2018.99028

J. Kitzen, J. Pergolizzi, Robert Taylor, R. Raffa

{"title":"Crisaborole和Apremilast:具有相似作用机制，不同适应症的PDE4抑制剂用于炎症性皮肤病的治疗","authors":"J. Kitzen, J. Pergolizzi, Robert Taylor, R. Raffa","doi":"10.4236/PP.2018.99028","DOIUrl":null,"url":null,"abstract":"Two \nselective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, \nPfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United \nStates Food and Drug Administration for the treatment of related but different \ndermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, \nrespectively). The purpose of this review is to summarize the underlying \nbiochemistry and pathophysiology associated with these dermatologic conditions, \nreview the chemistry, pharmacology and safety of each of these products, and \npresent preclinical and clinical evidence that may help explain why these two \nPDE4 inhibitors offer new treatment options for these skin conditions.","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions\",\"authors\":\"J. Kitzen, J. Pergolizzi, Robert Taylor, R. Raffa\",\"doi\":\"10.4236/PP.2018.99028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Two \\nselective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, \\nPfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United \\nStates Food and Drug Administration for the treatment of related but different \\ndermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, \\nrespectively). The purpose of this review is to summarize the underlying \\nbiochemistry and pathophysiology associated with these dermatologic conditions, \\nreview the chemistry, pharmacology and safety of each of these products, and \\npresent preclinical and clinical evidence that may help explain why these two \\nPDE4 inhibitors offer new treatment options for these skin conditions.\",\"PeriodicalId\":19875,\"journal\":{\"name\":\"Pharmacology & Pharmacy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology & Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4236/PP.2018.99028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2018.99028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

摘要

两种选择性磷酸二酯酶-4 (PDE4)抑制剂crisaborole (Eucrisa®，Pfizer)和apremilast (Otezla®，Celgene)最近获得了美国食品和药物管理局的批准，用于治疗相关但不同的皮肤病(分别为特应性皮炎和斑块性牛皮癣)。本综述的目的是总结与这些皮肤疾病相关的潜在生物化学和病理生理学，回顾每种产品的化学，药理学和安全性，并提出临床前和临床证据，可能有助于解释为什么这两种PDE4抑制剂为这些皮肤疾病提供了新的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions

Two selective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, Pfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United States Food and Drug Administration for the treatment of related but different dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, respectively). The purpose of this review is to summarize the underlying biochemistry and pathophysiology associated with these dermatologic conditions, review the chemistry, pharmacology and safety of each of these products, and present preclinical and clinical evidence that may help explain why these two PDE4 inhibitors offer new treatment options for these skin conditions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacology & Pharmacy

自引率

0.00%

发文量